Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,147Revenue $M54.8Net Margin (%)-152.3Z-Score1.9
Enterprise Value $M1,032EPS $-0.7Operating Margin %-146.8F-Score3
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-152.3Higher ROA y-yN
Price/Book17.410-y EBITDA Growth Rate %8.2Quick Ratio5.1Cash flow > EarningsY
Price/Sales19.15-y EBITDA Growth Rate %-0.6Current Ratio5.3Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-82.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M125ROI % (ttm)-92.5Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
HALOJohn Burbank 2014-03-31 Buy 0.01%$12.11 - $17.57
$ 9.29-38%New holding, 15773 sh.15,773
HALOJean-Marie Eveillard 2013-12-31 Buy 0.05%$9.66 - $15.7
$ 9.29-28%New holding, 1294580 sh.1,294,580
HALOJohn Burbank 2012-12-31 Sold Out -0.17%$4.82 - $7.07
$ 9.2959%Sold Out0
HALOJohn Burbank 2012-09-30 Add0.07%$4.28 - $9.78
$ 9.2927%Add 66.67%500,000
HALOJohn Burbank 2012-06-30 Add0.03%$7.32 - $13
$ 9.296%Add 50%300,000
HALOJohn Burbank 2012-03-31 Buy 0.09%$9.22 - $13.35
$ 9.29-12%New holding, 200000 sh.200,000
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
$ 9.2913%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
$ 9.2940%New holding, 17100 sh.17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HALO John Burbank 2014-03-3115,7730.010.01New Buy
HALO Jean-Marie Eveillard 2014-03-311,433,7801.150.05+10.75%
Premium Most recent portfolio changes are included for Premium Members only!

HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Engler RobertDirector 2014-05-15Sell126,700$7.5619.97view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.13-0.66view
Shepard H. MichaelVP, Chief Scientific Officer 2013-08-19Sell10,000$7.1127.57view
FALBERG KATHRYN EDirector 2013-08-14Buy100,000$6.8232.99view
Engler RobertDirector 2012-11-29Buy15,000$5.5762.84view
Shaffer James PVP & Chief Commercial Officer 2012-11-14Buy20,000$5.2273.75view
FALBERG KATHRYN EDirector 2012-11-13Buy50,000$5.2174.09view
Kelley Kenneth JDirector 2012-08-27Buy20,000$5.759.12view
Frost Gregory IanCEO, President 2012-08-13Buy2,000$5.564.91view
KIRK RANDAL JDirector, 10% Owner 2012-06-05Buy194,189$7.3822.9view

Press Releases about HALO :

    Quarterly/Annual Reports about HALO:

    News about HALO:

    Articles On GuruFocus.com
    comment on HALO May 12 2013 
    comment on HALO May 12 2013 
    comment on HALO May 12 2013 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
    Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 
    Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 
    Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Re Jul 31 2009 

    More From Other Websites
    Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
    9:06 am Halozyme Therapeutics resumes patient enrollment and dosing in PEGPH20 clinical program in... Jul 22 2014
    Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
    Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Jul 21 2014
    BUZZ-U.S. Stocks on the Move-Isle of Capri, Intercloud, Rent-A-Center Jul 11 2014
    Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer... Jul 08 2014
    Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme Jun 25 2014
    Halozyme Therapeutics To Present At The JMP Securities 2014 Healthcare Conference Jun 17 2014
    Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th... Jun 15 2014
    Halozyme Therapeutics (HALO) In A Perilous Reversal Jun 13 2014
    Halozyme Therapeutics upgraded by UBS Jun 12 2014
    The Zacks Analyst Blog Highlights: Clovis, Biogen, Halozyme, Ariad and Chart Industries Jun 12 2014
    Why Halozyme Therapeutics Was Upgraded To 'Buy' This Morning Jun 12 2014
    Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted Jun 11 2014
    Today's Perilous Reversal Stock: Halozyme Therapeutics (HALO) Jun 06 2014
    Halozyme Therapeutics, Inc. (HALO) in Focus: Stock Surges 12.00% Jun 06 2014
    Halozyme Study Clinical Hold Lifted by FDA Jun 05 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    Email Hide